Adalimumab & ustekinumab equally effective in bionaive Crohn's disease No difference across multiple endpoints after 52 weeks Both drugs highly effective: early therapy is key in CD Big missed opportunity with SEAVUE - no long-term data coming ... would love to see 2y outcomes

Not a surprise, but agreed about the 2 year point - shame!

Everyone likes numbers… gastro.org/clinical-guida…

I think we’re all glad to have some evidence for this clearly well-needed patient-centred approach

Pleasure to present our abstract at #BSGLIVE23 on behalf of #GSTTnhs

Excited to see the release of the new GLINT Research Group quarterly newsletter, Digest This! that went out this evening! Do check your junk mail and add us to your mailing list. Interested in signing up? Email [email protected] #gastro #research #GITwitter

UPDATE - GLINT is launching a brand new study on endoscopic dilatation for benign oesophageal strictures - data collection will start end of Jan/early Feb’24, but sites are still being recruited so contact us to join as a UK site before we finish! #gastro #GITwitter #research

Risankizumab in refractory #CD patients N=53 👫51% B2 & 17% B3 behavior Perianal dis 47% Prior bowel 🔪 79% All had failed at least to 1 antiTNF (>90% to two) + VDZ + UST (and some received off label TOFA) ✅75% persisted at w52 Dont miss out our latest publication

Very excited to publish UK real-world on Risankizumab use for refractory Crohn’s in #FrontGastro_BMJ